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Human lactotransferrin receptors have been recently characterized on mitogen-stimulated human lymphocytes [(1989) 
Eur. J. Biochem. 179, 481-487]. In order to define the lactotransferrin recognition site by these receptors, the binding 
to lymphocytes of several tryptic fragments, isolated from human lactotransferrin bymild tryptic hydrolysis [(1984) Bio- 
chim. Biophys. Acta 787, 90-96]; has been investigated. The 30 kDa N-tryptic fragment (residues 4-281) and the re-asso- 
ciated N,C-tryptic complex bind to lactotansferrin lymphocyte receptor with a dissociation constant of 44 nM and 39 
nM, respectively, similar to the value obtained for the native lactotransferrin (Kd = 46 riM). However, neither the N-termi- 
nal domain II (residues 91-257) nor the 50 kDa C-tryptic fragment (residues 282-703) are recognized. These results ug- 
gest that the binding site of human lactotransferrin by the lymphocyte receptor is located in the N-terminal lobe and 
more precisely in the N-terminal domain I (residues 4-90 and/or 258-281). 
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1. INTRODUCTION 
Lactotransferrin, also called lactoferrin, sero- 
transferrin and ovotransferrin are bilobed iron- 
binding glycoproteins of the transferrin class 
whose primary structure [1-3] and three- 
dimensional conformation, as revealed by partial 
proteolytic hydrolysis tudies [4-61 and X-ray dif- 
fraction data [7,8], are very similar. However, 
these glycoproteins differ in the number, the struc- 
ture and the location of their glycans [9-12]. Other- 
wise, these transferrins bind to different cells such 
as reticulocytes ( erotransferrin) [131, enterocytes 
(lactotransferrin) [14,15] and chick embryo red 
blood cells (ovotransferrin) [16], thus suggesting 
that specific transferrin receptors are present at the 
surface of these cells and recognize a glycan, a 
peculiar egion of the polypeptide chain, or both. 
Up to now, very few data are available about he 
transferrin recognition site on these cells. The re- 
cent characterization f a specific lactotransferrin 
receptor, at the surface of phytohemagglutinin- 
stimulated human peripheral blood lymphocytes 
[17], prompted us to define the region of the 
human lactotransferrin molecule which interacts 
with this kind of receptors. The analysis was per- 
formed by using different fragments previously 
isolated from human lactotransferrin by mild tryp- 
tic hydrolysis [6]. Moreover, in order to point out 
the importance of the lactotransferrin molecule 
conformation i the interaction with its receptor, 
the binding and competition experiments were per- 
formed in the presence of the re-associated N,C- 
tryptic complex whose conformation is slightly 
modified compared to lactotransferrin [18]. 
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2. MATERIALS AND METHODS 
2.1. Proteins 
Lactotransferrin purified from human lactoserum [ll] was 
iron-saturated [19] and submitted to a mild tryptic hydrolysis [6] 
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in order to isolate the 30 kDa monoferric N-tryptic fragment 
(residues 4-281) and the 50 kDa monoferric C-tryptic fragment 
(residues 282-703). Both 30 kDa N- and 50 kDa C-tryptic 
fragments were re-associated into a non-covalent N,C-tryptic 
complex [18]. In addition; an iron-binding 20 kDa glycopeptide 
(residues 91-257) called N2-glycopeptide, which corresponds to
the N-terminal domain II of human lactotransferrin described 
by Anderson et al. [7], was prepared from tryptic hydrolysate of
the 30 kDa N-tryptic fragment [6]. 
2.2. Cells 
Human peripheral blood lymphocytes were isolated from 
heparinized whole blood and stimulated with phytohemag- 
glutinin (IBF, Villeneuve la Garenne, France) as previously 
described [17]. 
2.3. Binding assays 
Proteins were labelled with Na125I (Amersham International, 
England) by using lodo-Gen (Pierce Chemical Co., Rotterdam, 
The Netherlands) as a catalyst [17]. The cell binding of labelled 
human lactotransferrin a d of its different fragments described 
above was performed in siliconized polypropylene tubes 
(Minisorb, Nunc, Denmark). Before use, cells were washed 
twice in RPMI 1640 without fetal calf serum and resuspended in 
RPMI 1640, 25 mM Hepes, pH 7.3, in order to obtain a cell 
concentration of about 5 x 10 s cells/ml, t25I-labelled lac- 
totransferrin was added to the cell suspension ata concentration 
ranging from 0 to 100 nM and, after 2 h at 4°C, the cells were 
run (2000 x g, 10 rain) and washed three times with phosphate- 
buffered saline. All assays were performed in the presence of 
0.2% human serotransferrin, ot recognized by the lac- 
totransferrin receptors [17], in order to limit the important ad- 
sorption of lactotransferrin o to the walls of the incubation 
vials. Non-specific binding was estimated by adding a 100-molar 
excess of unlabelled lactotransferrin. The dissociation constants 
(Kd) and the number of binding sites (n) were determined by 
Scatchard plot analysis [20]. 
2.4. Competitive binding assays 
The inhibition of 125I-labelled human lactotransferrin binding 
by the N- and C-tryptic fragments, the N2-glycopeptide, and by 
the re-associated N,C-tryptic complex was assayed in the 
presence of 5-100-fold molar excess of each unlabelled polypep- 
tide. Binding assays were carried out as described above. 
3. RESULTS 
3.1. Binding assays 
As shown in fig. 1, the binding of the N-tryptic 
fragment and of the re-constituted N,C-tryptic 
complex was concentration-dependent from 0 to 
20 nM and saturable at about 100 nM, with respec- 
tive dissociation constants of Kd = 44 _+ 4 and 
39 _+ 6 nM, similar to that of human lactotransfer- 
rin which was used as a reference (Kd= 
46 _+ 3 nM). However, the number of binding sites 
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Fig. 1. Specific binding of 1251-labelled iron saturated human lac- 
totransferrin (-* -'), re-associated N,C-tryptic complex 
(O---e),  N-tryptic fragment (.- =), C-tryptic fragment 
(A zx) and N2-glycopeptide ((3-------0) to phytohemagglutinin- 
stimulated human lymphocytes. Equilibrium bindings were 
measured at 4°C using 0.5 × 104 cells per sample. Results were 
calculated from three separate xperiments. 
associated N,C-tryptic complex (n = 170000) was 
2-fold lower than the native protein (n = 300 000). 
On the contrary, the binding of both C-tryptic 
fragment and N2-glycopeptide to mitogen- 
stimulated lymphocytes only represented 10070 of 
human lactotransferrin binding and was not 
saturable, suggesting a non-specific binding. 
3.2. Competitive binding assays 
Competition experiments were performed be- 
tween t2SI-labelled lactotransferrin a d unlabelled 
peptides and as shown in fig.2, the radiolabelled 
lactotransferrin binding to mitogen-stimulated 
human lymphocytes was 55070 inhibited by 100-fold 
molar excess of unlabelled human lactotransferrin. 
In the same experimental conditions, the re- 
associated N,C-tryptic omplex and the N-tryptic 
fragment blocked the labelled lactotransferrin 
binding with 45% and 32070 inhibition, respec- 
tively. 
Furthermore, neither the C-tryptic fragment nor 
the N2-glycopeptide significantly inhibited the lac- 
totransferrin binding on mitogen-stimulated lym- 
phocytes since no more than 5°/o inhibition was ob- 
tained for both tryptic fragments (fig.2). These 
results are in good agreement with the binding ex- 
periments described above. 
4. DISCUSSION 
The preliminary results we have obtained in- 
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Fig.2. Competitive bindings to phytohemagglutinin-stimulated 
human lymphocytes between 1251-labelled human lactotransfer- 
rin and competitors such as: human lactotransferrin (*- *--), 
re-associated N,C-tryptic omplex (~---~), N-tryptic fragment 
( i - - i ) ,  C-tryptic fragment (a 4) and N2-glycopeptide 
(O---O). Competitive bindings were measured at 4°C using 
1 × 106 cells per sample. Each point represents he average of 
duplicate measurements from two separate xperiments. 
binding experiments with labelled fragments and 
the competitive assays with unlabelled fragments 
demonstrate that protein iodination does not 
modify the lactotransferrin binding to lympho- 
cytes. These results differ from those obtained by 
Mason and Brown [21] who have shown that 
isolated N- and C-terminal lobes of hen ovotrans- 
ferrin cannot bind to chick embryo red blood cells. 
However, when both the lobes, re-associated or
not, are present binding occurs [22]. Moreover, 
iodination experiments have underlined the im- 
plication of a tyrosinyl residue at the C-terminal 
lobe of hen ovotransferrin i  receptor recognition 
[21]. Thus, it appears that the interactions of 
human lactotransferrin and hen ovotransferrin 
with their specific receptor are different. 
Further investigations are being engaged in order 
to locate more precisely the human lactotransferrin 
peptide sequence which interacts with phytohemag- 
glutinin-stimulated human lymphocyte r ceptors. 
dicate, that the N-tryptic fragment and the re- 
associated N,C-tryptic omplex are recognized by 
the receptors with the same affinity as that of lacto- 
transferrin. Nex, ertheless, the lower number of 
binding sites of these tryptic fragments could be ex- 
plained by secondary-structure modifications, 
mainly located in the N-tryptic fragment. As a mat- 
ter of fact, the isolation of the N- and C-tryptic 
fragments leads to a decrease of about 30°70 of the 
a-helical content and during the non-covalent re- 
association of both N- and C-tryptic fragments in- 
to the so-called N,N-tryptic omplex, the confor- 
mation of the native lactotransferrin is restored on- 
ly in part [18]. These observations point out the im- 
portance of the protein conformation to lympho- 
cyte receptor binding. Moreover, the lactotransfer- 
rin recognition site seems to be located precisely in 
the N-terminal domain I (residues 4-90 and 
258-281) described by Anderson et al. [7] because 
the N2-glycopeptide (residues 91-257), correspon- 
ding to the N-terminal domain II, was not bound to 
the lymphocyte receptor. Up to now, the N- 
terminal domain I has not been isolated because of 
its degradation during tryptic hydrolysis. The 
glycan does not seem to be involved in the binding 
to lymphocyte r ceptors since neither the N2-glyco- 
peptide nor the C-tryptic fragment, each contain- 
ing one glycan, were recognized. In addition, the 
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